Loading...
•
Jun 30, 2024
Ultragenyx Q2 2024 Earnings Report
Ultragenyx's financial performance in Q2 2024 was driven by revenue growth across commercial therapies due to increasing global demand, leading to raised total revenue guidance for the year.
Key Takeaways
Ultragenyx reported a strong second quarter in 2024, with total revenue reaching $147 million, a 36% increase compared to the same period in 2023. The company raised its total revenue guidance for 2024 to $530 million to $550 million. Positive data was reported from Phase 1/2, Phase 2/3, and Phase 3 studies.
Total revenue for the second quarter of 2024 was $147 million, a 36% increase year-over-year.
Crysvita revenue for the second quarter of 2024 was $114 million, a 37% increase year-over-year.
Dojolvi revenue for the second quarter of 2024 was $19 million, a 17% increase year-over-year.
Evkeeza revenue for the second quarter of 2024 was $8 million, driven by demand outside the United States.
Ultragenyx
Ultragenyx
Ultragenyx Revenue by Segment
Revenue by Segment
Crysvita Revenue
CapyFin.comDojolvi Revenue
CapyFin.comEvkeeza Revenue
CapyFin.comMepsevii Revenue
CapyFin.com Forward Guidance
Total revenue guidance increased to be in the range of $530 million to $550 million.
Positive Outlook
- Total revenue guidance increased to be in the range of $530 million to $550 million (previously $500 million to $530 million)
- Crysvita revenue expected to be towards the upper end of the range of $375 million to $400 million.
- Crysvita revenue includes all regions where Ultragenyx will recognize revenue: product sales in Latin America and Turkey, royalties in Europe, which have been ongoing, and royalties in North America, which began in April 2023.
- Dojolvi revenue in the range of $75 million to $80 million
- Net Cash Used in Operations less than $400 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income